| Literature DB >> 35941635 |
Lena Cetrelli1,2,3, Athanasia Bletsa4,5, Anette Lundestad6,7, Elisabet Grut Gil5, Johannes Fischer5, Josefine Halbig8,9, Paula Frid8,10,11, Oskar Angenete12,13, Ingrid Lillevoll14, Annika Rosén5,15, Karin B Tylleskär16, Keio Luukko5, Ellen Nordal9,17, Anne Nordrehaug Åstrøm4,5, Marit Slåttelid Skeie14,5, Astrid Jullumstrø Feuerherm14, Abhijit Sen14,6, Marite Rygg6,7.
Abstract
BACKGROUND: Vitamin D deficiency has been associated with autoimmune diseases and oral health. Knowledge about the association between vitamin D status and oral conditions in JIA is limited. We aimed to investigate vitamin D status in a cohort of Norwegian children and adolescents with JIA and possible associations between serum vitamin D levels, clinical indicators of oral health, and JIA disease characteristics.Entities:
Keywords: 25(OH) vitamin D; Adolescents; Children; Dental caries; Disease activity; Gingival inflammation; Juvenile arthritis; Oral health; Rheumatic disease; Vitamin D insufficiency
Mesh:
Substances:
Year: 2022 PMID: 35941635 PMCID: PMC9361556 DOI: 10.1186/s12903-022-02349-1
Source DB: PubMed Journal: BMC Oral Health ISSN: 1472-6831 Impact factor: 3.747
Clinical characteristics of children in the NorJIA study population, N = 223
| Characteristics at study visit | Values |
|---|---|
| Girls, n (%) | 132 (59.2) |
| Age at examination, median years, (IQR) | 12.6 (9.4–14.7) |
| Caucasian, n (%) | 217 (97.3) |
| Overweight/obesitya, n (%) | 53 (23.8) |
| Parental education levelb, n (%) | |
| Low | 64 (30.3) |
| High | 147 (69.7) |
| Age at disease onset, median years, (IQR) | 5.8 (2.3–10.3) |
| Disease duration, median years, (IQR) | 4.6 (2.6–8.2) |
| Oligoarticular arthritis, persistent or extended, n (%) | 99 (44.4) |
| Not in remission off medicationc, n (%) | 194 (87.0) |
| Ongoing medicationd, n (%) | |
| DMARDs | 148 (66.4) |
| bDMARDs | 87 (39.0) |
| Systemic corticosteroids | 4 (1.8) |
| NSAIDs | 71 (31.8) |
| Number of children with active joints, n (%) | 51 (22.9) |
| VAS pain > 0 e, mean (± SD) | 2.0 (± 2.2) |
NorJIA, Norwegian juvenile idiopathic arthritis; IQR, inter-quartile range (25th–75th percentile); DMARDs, disease-modifying anti-rheumatic drugs, including both synthetic and biologic DMARDs; bDMARDs, only biologic DMARDs; NSAIDs, non-steroid anti-inflammatory drugs; VAS, Visual Analogue Scale; SD, standard deviation
aAge- and sex-adjusted body mass index (iso-BMI) according to the International Obesity Task Force recommendations corresponding to adult BMI (overweight: BMI = 25–29.9, obesity BMI ≥ 30), overweight and obesity combined
bLow level was defined as primary and high school (education ≤ 13 years), High was defined as university education, the parent with the highest education level defined the level for both parents, n = 211 (12 missing)
cDisease status categorized according to Wallace et al. 2004/2011
dMedication ongoing at study visit: DMARDs include both synthetic (methotrexate, hydroxychlorochine, cyclosporine or mycophenolate mofetil) and/or biologic (etanercept, infliximab, adalimumab, tocilizumab, abatacept, certolizumab, golimumab or rituximab), Systemic corticosteroids oral or intravenous
eMean self-reported disease-related pain measured on a 21-numbered circle VAS scale, 0–10 cm (0 = no pain, 10 = maximum pain, 5 missing), VAS > 0 n = 136
Serum and dietary vitamin D status in the NorJIA study population, N = 223
| Serum and dietary vitamin D | Values | |
|---|---|---|
| Serum 25(OH) vit. Da, nmol/L, mean (± SD) | 61.4 (± 22.3) | |
| Serum 25(OH) vit. D in categories, n (%) | ||
| Deficient < 30 (nmol/L) | 15 (6.7) | |
| Insufficient 30–49 (nmol/L) | 51 (22.9) | |
| Sufficient 50–74 (nmol/L) | 100 (44.8) | |
| Desired ≥ 75–150 (nmol/L) | 57 (25.6) | |
| Seasonal serum 25(OH) vit. Db, nmol/L, mean (± SD) | ||
| Winter, December-February (n = 49) | 51.4 (± 21.2) | |
| Spring, March–May (n = 66) | 55.6 (± 18.8) | |
| Summer, June–August (n = 25) | 72.5 (± 21.6) | |
| Fall, September–November (n = 83) | 68.8 (± 22.1) | |
| Daily vit. D intakec, µg/day, mean (± SD) | 11.2 (± 12.2) | |
| Northern Norway (n = 51) | 7.7 (± 8.4) | |
| Western Norway (n = 74) | 9.9 (± 11.8) | |
| Central Norway (n = 93) | 14.0 (± 13.6) | |
| Inadequate intaked, < 10 µg/day, n (%) | 144 (66.1) | |
| Supplemental vit. D intake, n (%) | 164 (75.2) | |
| Northern Norway | 34 (66.7) | |
| Western Norway | 49 (66.2) | |
| Central Norway | 81 (87.1) | |
NorJIA study, Norwegian juvenile idiopathic arthritis study; vit. D, vitamin D; SD, standard deviation
aSerum 25(OH) vitamin D collected during the study visits taking place throughout the calendar year, except for July
bSerum 25(OH) vitamin D collected during the four specified seasons
cEstimates of daily vit. D intake (dietary and supplemental) based on data from self-reported food frequency questionnaires (FFQ), n = 218 (5 participants did not fill in the FFQ), 164 participants reported supplemental vitamin D intake
d10 µg/day is the daily recommended intake of vit. D according to The Norwegian Directorate of Health and Nordic Nutrition Recommendations 2012 (5 participants did not fill in the FFQ)
Serum 25(OH) vitamin D levels according to demographics, anthropometrics, and disease characteristics
| Characteristics | Total N | Serum 25(OH) vit. D nmol/L mean (± SD) | Serum 25(OH) vit. D < 50 nmol/L n (%) |
|---|---|---|---|
| Geographical regions | |||
| North Norway | 56 | 56.1 (± 26.0) | 26 (46.4) |
| West Norway | 74 | 59.9 (± 19.5) | 20 (27.0) |
| Central Norway | 93 | 66.0 (± 21.3) | 20 (21.5) |
| Sex | |||
| Girls | 132 | 61.7 (± 22.5) | 39 (29.5) |
| Boys | 91 | 61.2 (± 22.1) | 27 (29.7) |
| Age groups, years | |||
| 4–9 | 62 | 69.2 (± 20.3) | 8 (12.9) |
| 10–12 | 58 | 62.7 (± 22.5) | 17 (29.3) |
| 13–16 | 103 | 56.1 (± 22.1) | 41 (39.8) |
| Iso-BMIa | |||
| Underweight | 13 | 67.2 (± 23.0) | 3 (23.1) |
| Normal weight | 157 | 64.0 (± 21.6) | 39 (24.8) |
| Overweight | 43 | 55.6 (± 22.9) | 17 (39.5) |
| Obesity | 10 | 39.5 (± 13.1) | 7 (70.0) |
| Disease duration | |||
| < 4 years | 91 | 62.1 (± 23.8) | 26 (28.6) |
| ≥ 4 years | 132 | 61.1 (± 21.3) | 40 (30.3) |
| JIA categoriesb | |||
| Systemic | 7 | 80.7 (± 26.6) | 1 (14.3) |
| Oligoarticular persistent | 77 | 63.6 (± 21.7) | 18 (23.4) |
| Oligoarticular extended | 22 | 59.0 (± 19.8) | 7 (31.8) |
| Polyarticular RF negative | 50 | 57.7 (± 20.6) | 20 (40.0) |
| Polyarticular RF positive | 4 | 70.8 (± 39.9) | 1 (25.0) |
| Psoriatic arthritis | 9 | 53.1 (± 21.0) | 5 (55.6) |
| Enthesitis-related arthritis | 23 | 56.7 (± 20.0) | 7 (30.4) |
| Undifferentiated arthritis | 31 | 64.5 (± 25.0) | 7 (22.6) |
| Disease statusc | |||
| Remission off medication | 29 | 58.0 (± 22.8) | 10 (34.5) |
| Inactive disease | 105 | 63.3 (± 23.3) | 30 (28.6) |
| Active disease | 89 | 60.5 (± 21.0) | 26 (29.2) |
| Active joints | |||
| No | 172 | 61.3 (± 22.0) | 50 (29.1) |
| Yes | 51 | 62.1 (± 23.5) | 16 (31.4) |
| Medication | |||
| DMARDsd | |||
| Never used | 52 | 58.3 (± 21.2) | 15 (28.8) |
| Ever used | 171 | 62.4 (± 22.6) | 51 (29.8) |
| Ongoing | 148 | 62.8 (± 22.9) | 44 (29.7) |
| Systemic corticosteroidse | |||
| Never used | 175 | 61.6 (± 22.6) | 48 (27.4) |
| Ever used | 48 | 60.9 (± 21.5) | 18 (37.5) |
| Ongoing | 4 | 77.8 (± 42.6) | 1 (25.0) |
| Painf | |||
| VAS pain = 0 | 82 | 59.1 (± 20.8) | 26 (31.7) |
| VAS pain > 0 | 136 | 62.9 (± 22.4) | 37 (27.2) |
DMARDs, disease-modifying anti-rheumatic drugs; vit. D, vitamin D; SD, standard deviation; ILAR, International League of Association for Rheumatology; RF, rheumatoid factor; VAS, Visual Analogue Scale
aBody mass index (BMI) adjusted for age and sex according to the International Obesity Task Force recommendations corresponding to adult BMI (kg/m2) (underweight: < 18.5, normal weight: 18.5–24.9, overweight: 25–29.9, obesity: ≥ 30)
bAccording to the ILAR classification criteria
cDisease status was categorized according to the definition by Wallace et al. 2004/2011. Remission off medication = inactive disease off medication for ≥ 12 months. Inactive = inactive disease on medication for < 6 months, or off medication < 12 months, or remission on medication (inactive disease on medication for ≥ 6 months). Active = continuous active disease or flare
dMedication; never used, ever used (= previous, and ongoing at study visit)
DMARDs include both synthetic (methotrexate, hydroxychlorochine, cyclosporine or mycophenolate mofetil) and biologic (etanercept, infliximab, adalimumab, tocilizumab, abatacept, certolizumab, golimumab or rituximab)
eSystemic corticosteroids include oral or intravenous corticosteroids
fSelf-reported disease-related pain measured on a 21-numbered circle VAS scale (0 = no pain, 10 = maximum pain) (5 missing)
Serum 25(OH) vitamin D levels according to oral health conditions
| Oral health conditions | Total N | Serum 25(OH) vit. D, nmol/LMean (± SD) |
|---|---|---|
| Cariesa | ||
| No | 157 | 65.2 (± 21.1) |
| Yes | 61 | 52.0 (± 23.4) |
| Hypoplasiab | ||
| No | 213 | 61.7 (± 22.4) |
| Yes | 10 | 55.6 (± 20.2) |
| Opacityb | ||
| No | 132 | 62.5 (± 20.8) |
| Yes | 91 | 60.0 (± 24.3) |
| Post-eruptive breakdownb | ||
| No | 213 | 61.8 (± 22.6) |
| Yes | 10 | 55.4 (± 14.0) |
| Dental erosionc | ||
| No | 74 | 59.3 (± 24.4) |
| Yes | 97 | 59.5 (± 21.1) |
| GBId | ||
| Low | 114 | 59.5 (± 20.4) |
| Middle/high | 44 | 55.4 (± 27.4) |
| DI-Se | ||
| Low | 87 | 55.2 (± 22.6) |
| Middle/high | 54 | 60.7 (± 22.9) |
| OHI-Sf | ||
| Low | 84 | 55.2 (± 22.4) |
| Middle/high | 57 | 60.5 (± 23.2) |
SD, standard deviation; vit., vitamin; GBI, Gingival Bleeding Index; DI-S, Debris Index simplified (dental bacterial plaque); OHI-S, Oral Hygiene Index simplified
aCaries included dentin caries (grade 3–5, Amarante 1998) and filled teeth in primary second molars and permanent first molars (5 did not have caries registration)
bEnamel defects (Brook et al. 2001, Elcock et al. 2006) include Hypoplasia = areas on the tooth with thin enamel, Opacity = opaque white or yellow hypomineralized areas, Post-eruptive breakdown = loss of enamel after tooth eruption
cDental erosion (Hasselkvist et al. 2010, Johansson et al. 1996) include buccal and lingual surface erosion, and occlusal cupping. Children aged 4–5 and 10–16 years included (2 did not have the examination)
dGBI (Ainamo & Bay, 1975), categorized into two levels; the lowest third and a combination of the middle and highest thirds of GBI scores. Children aged 10–16 years included (3 did not have the examination)
eDI-S (Greene & Vermillion, 1964), categorized into two levels; the lowest third and a combination of the middle and highest thirds of DI-S scores. Children aged 10–16 years included (20 missing as those with fixed orthodontic appliances were excluded in these analysis)
fOHI-S (Greene & Vermillion, 1964) = the sum of Debris Index and Calculus index, categorized into two levels; the lowest third and a combination of the middle and highest thirds of OHI-S scores. Children aged 10–16 years included (20 missing due to fixed orthodontic appliances)
Multivariable logistic regression analysis between serum vitamin D levels and JIA- related outcomes
| JIA-related outcomes | Yes/No | Serum 25(OH) vit. Das exposure | Model 1 |
|---|---|---|---|
| Disease duration ≥ 4 yearsb | 92/65 | ≥ 50 nmol/L | 1 (ref.) |
| 40/26 | < 50 nmol/L | 0.83 (0.43–1.60) | |
| Not oligo persistent JIAc | 98/59 | ≥ 50 nmol/L | 1 (ref.) |
| 48/18 | < 50 nmol/L | 1.54 (0.77–3.10) | |
| DMARDs ever usedd | 120/37 | ≥ 50 nmol/L | 1 (ref.) |
| 51/15 | < 50 nmol/L | 1.29 (0.58–2.87) | |
| Not in remission off medicatione | 138/19 | ≥ 50 nmol/L | 1 (ref.) |
| 56/10 | < 50 nmol/L | 0.81 (0.32–2.07) | |
| Active jointsf | 35/122 | ≥ 50 nmol/L | 1 (ref.) |
| 16/50 | < 50 nmol/L | 1.07 (0.51–2.24) | |
| VAS pain > 0 g | 99/56 | ≥ 50 nmol/L | 1 (ref.) |
| 37/26 | < 50 nmol/L | 0.64 (0.33–1.24) |
The column Yes/No, N shows the number of participants with (Yes) and without (No) the JIA-related outcome within each of the two vitamin D exposure groups ≥ 50 nmol/L and < 50 nmol/L
Vit., vitamin; JIA, juvenile idiopathic arthritis; OR, odds ratio; CI, confidence interval; DMARDs, disease-modifying anti-rheumatic drugs; VAS, Visual Analog Scale; iso-BMI, Body Mass Index adjusted for age and sex, corresponding to adult BMI according to International Obesity Task Force; ILAR, International League of Association for Rheumatology
aModel 1: Adjusted for age, sex, geographical region, iso-BMI, and blood sampling performed in 4 seasons (summer, fall, winter, spring)
bDisease duration was categorized into: < 4 years and ≥ 4 years
cJIA categories defined according to the ILAR classification criteria and categorized into oligoarticular persistent JIA (the mildest form), and all other JIA categories
dDMARDs include both synthetic (methotrexate, hydroxychloroquine, cyclosporine, mycophenolate mofetil) and biologic (etanercept, infliximab, adalimumab, tocilizumab, abatacept, certolizumab, golimumab, rituximab) and categorized into never used, and ever used (= previous, or ongoing medication)
eDisease activity (Wallace et al. 2004/2011), categorized into not in remission off medication, and remission off medication
fActive joints at the study visit = children without active joints, and those with one or more active joints
gSelf-reported disease-related pain measured on a 21-numbered circle VAS scale (0 = no pain, 10 = maximum pain) and categorized into no pain (VAS = 0), and pain (VAS > 0) (5 missing)
Multivariable logistic regression analysis between serum vitamin D levels and oral health
| Oral health outcomes | Yes/no | Serum | Model 1a | Model 2b |
|---|---|---|---|---|
| Cariesc | 30/123 | ≥ 50 nmol/L | 1 (ref.) | 1 (ref.) |
| 31/34 | < 50 nmol/ L | 2.88 (1.44–5.78) | 2.89 (1.43–5.86) | |
| Hypoplasiad | 6/151 | ≥ 50 nmol/L | 1 (ref.) | 1 (ref.) |
| 4/62 | < 50 nmol/L | 2.01 (0.48–8.46) | 2.04 (0.49–8.52) | |
| Opacityd | 63/94 | ≥ 50 nmol/L | 1 (ref.) | 1 (ref.) |
| 28/38 | < 50 nmol/L | 1.03 (0.49–1.75) | 0.93 (0.49–1.76) | |
| Post-eruptive breakdownd | 8/149 | ≥ 50 nmol/L | 1 (ref.) | 1 (ref.) |
| 2/64 | < 50 nmol/L | 0.50 (0.91–2.79) | 0.47 (0.08–2.66) | |
| Dental erosione | 65/48 | ≥ 50 nmol/L | 1 (ref.) | 1 (ref.) |
| 32/26 | < 50 nmol/L | 1.13 (0.54–2.34) | 1.13 (0.54–2.34) | |
| GBI, middle/highf | 21/79 | ≥ 50 nmol/L | 1 (ref.) | 1 (ref.) |
| 23/35 | < 50 nmol/L | 2.32 (1.09–4.93) | 2.36 (1.10–5.01) | |
| DI-S, middle/highg | 38/49 | ≥ 50 nmol/L | 1 (ref.) | 1 (ref.) |
| 16/38 | < 50 nmol/L | 0.72 (0.33–1.61) | 0.72 (0.32–1.60) | |
| OHI-S, middle/highh | 39/48 | ≥ 50 nmol/L | 1 (ref.) | 1 (ref.) |
| 18/36 | < 50 nmol/L | 0.82 (0.37–1.82) | 0.81 (0.36–1.79) |
In the column Yes/No, N shows the number of participants with (Yes) and without (No) the JIA-related outcome within each of the two vitamin D exposure groups ≥ 50 nmol/L and < 50 nmol/L
OR, odds ratio; CI, confidence interval; vit. D, vitamin D; iso-BMI, Body Mass Index adjusted for age and sex; DMARDs, disease-modifying anti-rheumatic drugs; GBI, Gingival Bleeding Index; DI-S, simplified Debris Index; OHI-S, = simplified Oral Hygiene Index
aModel 1: Adjusted for age, sex, geographical region, iso-BMI, and season for blood sampling (summer, fall, winter, spring)
bModel 2: Model 1, and adjusted for DMARDs ever/never used
cCaries included dentin caries (grades 3–5) and filled teeth. Dichotomized into no caries (no) and caries (yes) (5 did not have caries registration)
dEnamel defects: Hypoplasia, Opacity and Post-eruptive breakdown (Brook et al. 2001, Elcock et al. 2006), categorized into not present(no), and present (yes). Children 4–16 years included
eDental erosion (Hasselkvist et al. 2010, Johansson et al. 1996) categorized into not present (no), and present (yes). Children aged 4–5 and 10–16 years included (2 did not have the examination)
fModified GBI (Ainamo & Bay, 1975), dichotomized into two levels of bleeding: Low = the lowest third (no), and Middle/High = a combination of the middle and highest third of scores (yes). Children aged 10–16 years included (3 missing)
gDI-S (Greene & Vermillion, 1964), dichotomized into two levels: Low = the lowest third (no), and Middle/High = a combination of the middle and highest third of scores (yes). Children aged 10–16 years included (20 missing due to fixed orthodontic appliances)
hModified OHI-S (Greene & Vermillion, 1964), dichotomized into two levels: low = the lowest third (no), and middle/high = a combination of the middle and highest third of scores (yes). Children aged 10–16 years included (20 missing due to fixed orthodontic appliances)